lncRNA影响乳腺癌化疗耐药性的研究进展

Research Progress on the Effect of lncRNA on Chemoresistance of Breast Cancer

目前lncRNA对乳腺癌化疗耐药的相关研究越来越多,本文重点就lncRNA对乳腺癌常见化疗药耐药的发生和发展中起的重要作用进行总结,并对lncRNA与乳腺癌化疗耐药之间的作用进行分析综合,讨论lncRNA作为乳腺癌化疗耐药的潜在靶点的治疗意义。本文总结国内外文献对lncRNA与乳腺癌一线化疗药物紫杉醇、多西他赛、阿霉素和顺铂的耐药相关研究进行综述。lncRNA介导乳腺癌化疗耐药的耐药机制包括:(1) 影响化疗药物靶基因的lncRNA及其影响效应。(2) lncRNAs通过调节乳腺癌细胞周期和细胞凋亡。(3) lncRNAs靶向PTE、NF-κB等信号通路。(4) lncRNAs影响多重耐药基因。lncRNA有望是改善乳腺癌患者化疗耐药的新靶点。以lncRNA为靶点可能是未来改善乳腺癌患者化疗效果的一种新策略。

At present, there are more and more researches on lncRNA in breast cancer chemotherapy resistance. This article focuses on the important role of lncRNA in the occurrence and development of common chemotherapy drug resistance in breast cancer, and analyzes and synthefies the role between lncRNA and breast cancer chemotherapy resistance to discuss the therapeutic significance of lncRNA as a potential target for chemoresistance in breast cancer. In this paper, the domestic and foreign literature on the relationship between lncRNA and the resistance of first-line chemotherapy drugs paclitaxel, docetaxel, doxorubicin and cisplatin in breast cancer is reviewed. The mechanisms of lncRNA-mediated chemoresistance in breast cancer include: (1) lncRNA affects the target genes of chemotherapy drugs and its effect, (2) lncRNAs regulate breast cancer cell cycle and apoptosis, (3) lncRNAs target PTE and NF-κB signaling pathways, (4) lncRNAs affect multidrug resistance genes. lncRNA is expected to be a new target for improving chemotherapy resistance in breast cancer patients. Targeting lncRNA may be a new strategy to improve the efficacy of chemotherapy in breast cancer patients in the future.